TESTOROX C250 ZEROX 10ml
Testorox C250 (TESTOSTERONE CYPIONATE)
Overview:
Testorox C250 is an injectable steroid containing 200mg/ml of Testosterone cypionate and it has been used for male hormone replacement therapy, hypogonadal disorders in men, treatment with low testosterone levels (and other conditions). Additionally, it is common to bodybuilding for muscle growth and recovery.
Indications:
- Addresses symptoms of male hypogonadism (low energy, low libido, erectile dysfunction, muscle loss + depression)
- In transgender men as MTF HRT to procreate male characteristics.
- Improves muscle mass and performance in bodybuilders
Contraindications:
- Testosterone Cypionate Intolerance
- E.g. Prostate or breast cancer in men
- Severe heart, liver or kidney disease
- Hypercalcemia
- Pregnancy or breastfeeding
- Severe sleep apnea
Administration:
Inject intramuscularly.
Average Dosage: 50-400 mg every2-4 weeks for hypogonadism; up to 2000mg weekly for bodybuilders.
Typically run 8-12 weeks with post-cycle therapy (PCT).
Medical Action:
Long-acting synthetic testosterone
Increases muscle mass, protein synthesis and red blood cell production.
Precautions:
- Check testosterone, and lipids & blood pressure.
- Regular prostate exams.
- Contraindications: CHF (caution), untreated OSA.
- Drug interactions, anti-doping rules.alert
Side Effects:
General: Irritation at injection site, acne and oily skin, balding of the scalp (in woman), aggression or sexual overstimulation.
Serious: Cardiovascular events, liver injury, exacerbation of sleep apnea – Elevated cholesterol levels – Polycythemia
Overdosage:
May result in severe complications. Get medical help fast. Treatment involves stopping the medications and symptom control.
While Testorox C250 is good for testosterone replacement therapy and sexual enhancement, it must be used with care along side regular monitoring to avoid possible side effects. As for anything in medicine, it is about balancing the risk and benefits to enable safe and effective use.
Reviews
There are no reviews yet.